

BEST AVAILABLE COPY

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

**(19) World Intellectual Property Organization
International Bureau**



(43) International Publication Date
30 September 2004 (30.09.2004)


PCT

(10) International Publication Number
WO 2004/083108 A1

(51) International Patent Classification ⁷ :	B81B 1/00	(SE). LINDMAN, Susanna [SE/SE]; Nåntuna Backe 49, S-757 59 Uppsala (SE).
(21) International Application Number:	PCT/SE2004/000440	(74) Agent: BERGANDER, Håkan; Uppsala Science Park, S-751 83 Uppsala (SE).
(22) International Filing Date:	23 March 2004 (23.03.2004)	
(25) Filing Language:	English	
(26) Publication Language:	English	
(30) Priority Data:		
0300823-2	23 March 2003 (23.03.2003)	SE
60/466,376	29 April 2003 (29.04.2003)	US
(71) Applicant (for all designated States except US):	GYROS AB [SE/SE]; Uppsala Science Park, S-751 83 Uppsala (SE).	
(72) Inventors; and		
(75) Inventors/Applicants (for US only):	INGANÄS, Mats [SE/SE]; Lapplandsresan 14, S-757 55 Uppsala (SE). DERAND, Helene [SE/SE]; Enstavägen 33, S-752 63 Täby	(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
(84) Designated States (unless otherwise indicated, for every kind of regional protection available):	ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK,	

[Continued on next page]

(54) Title: PRELOADED MICROSCALE DEVICES



(57) Abstract: A microfluidic device comprising one, two or more microchannel structures (101a-h), each of which comprises a reaction microcavity (104a-h) intended for retaining a solid phase material in the form of a wet porous bed. Each of said one, two or more microchannel structures comprises the solid phase material in a dry state together with a bed-preserving agent comprising one or more compounds having bed-preserving activity.



TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
ML, MR, NE, SN, TD, TG).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

Published:

— *with international search report*

PRELOADED MICROSCALE DEVICES

TECHNICAL FIELD

The invention relates to a microfluidic device for performing experiments which each comprises interaction between a solid phase material (= support material) and a solute 5 (S or S') that is present in a liquid. The solid phase material is present in the device as porous beds during the experiments. The device permits that one or more experiments can be carried out in parallel within the device.

Parallelity means that at least the interaction between the solute and the solid phase 10 material is carried out in parallel for two or more experiments. The reagents/reactants used may be different.

The term "solute" comprises true solutes, microorganisms including viruses, suspended cells, suspended cell parts and various other reactants that are in dissolved 15 or colloidal form and sufficiently small to be transported by liquid flow through the porous bed that is referred to herein.

The term "microfluidic device" means that the device comprises one or more microchannel structures in which liquid flow is used for transporting various kinds of 20 reactants, analytes, products, samples, buffers and/or the like. The terms "micro" in "microchannel structure" contemplates that there are one or more cavities and/or conduits that have a cross-sectional dimension that is $\leq 10^3$ μm , preferably $\leq 5 \times 10^2$ μm , such as $\leq 10^2$ μm . The device is capable of processing liquid aliquots in the nanolitre (nl) range (which includes the picolitre (pl) range). The nl-range has an 25 upper end of 5,000 nl but relates in most cases to volumes $\leq 1,000$ nl, such as ≤ 500 nl or ≤ 100 nl.

The interaction between the solute and the porous bed contemplates e.g.

- a) separation of the solute from the liquid, i.e. the solute is retained on the solid 30 phase material with the consequence that the porous bed plus the solute can be separated from the liquid,
- b) interaction as part of a catalytic reaction, e.g. an enzymatic reaction,
- c) solid phase synthesis, and/or

d) solid phase derivatization.

Patent publications (WO and US applications and issued US patents) cited herein are incorporated by reference in their entirety.

5

BACKGROUND PUBLICATIONS

WO 02075312 (Gyros AB) focuses on affinity assays for the characterization of reaction variables by binding a soluble affinity reactant to a solid phase material that comprises in immobilized form the counterpart to the affinity reactant. The solid 10 phase is represented by the inner wall of the reaction microcavity or by a porous bed placed in the reaction microcavity.

WO 03093802 (Gyros AB) describes performing catalytic assays with one part of the used catalytic system in immobilized form. The assays are illustrated with enzyme 15 systems. The immobilization techniques and solid phase materials are in principle the same as in WO 02075312 (Gyros AB).

US 5,726,026 (Univ. Pennsylvania) and US 5,928,880 (Univ. Pennsylvania) describe in a side sentence a microfluidic device that comprises a detection/reaction zone 20 containing a solid phase material in particle form. Streptavidin is immobilized to the particles. The particles may be dried or lyophilized.

US 6,479,299 (Caliper) discusses predispensation of soluble and insoluble reagents (assay components) during the manufacture of a microfluidic device. Insoluble 25 reagents may be in lyophilized form.

Applicant has marketed a microscale fluidic device (Gyrolab MALDI SP1) containing a plurality of microchannel structures each of which contains a column of a reverse solid phase material (hydrophobic beads) (WO 02075775 (Gyros AB) and WO 30 02075776 (Gyros AB)). The solid phase material is in a dry state. In order to secure that the beads are retained in the correct location during storage and transport, the packages of the devices have been specifically designed.

WO 00056808 (Gyros AB), WO 01047437 (Gyros AB), WO 01054810 (Gyros AB), WO 02075775 (Gyros AB) and WO 02075776 (Gyros AB) suggest in general terms to deliver microfluidic devices in dry form.

5 US 5,354,654 (Ligler et al) suggests a kit comprising a solid support with an immobilized ligand-receptor complex that has been lyophilized together with a cryostabilisator. Packing of the support in a macroscale column is suggested.

US 5,998,155 (Squibb) and US 5,691,152 (Squibb) describes compositions having a
10 high biotin-binding activity. The biotin-binding moiety is immobilized to a polymer support. The support may be in beaded form and lyophilized together with (a) a bulking agent protecting the beads from damages during freeze-drying and assisting the reswelling of the beads, (b) a protectant for inhibiting chemical reactions during freeze-drying and storage, (c) buffers etc.

15

BACKGROUND PROBLEMS

There are a number of technical problems associated with providing the market with microfluidic devices of the type discussed above. We have found that in the case the customer would introduce a hydrophilic porous bed into the device, there will be a
20 high risk for obtaining mal-functioning beds. In total this would lead to increased inter- and intra-device variations in performance of the beds/microchannel structures, decreased sensitivity and reproducibility for assays carried out in the structures, etc.

In the macroworld the general trend has been to provide preloaded columns with solid
25 phase based separation media in bed form in a wet state. Loss of liquid during storage due to evaporation typically is low compared to the total volume. The situation is quite different for microfluidic devices where bed volumes typically are in the nl-range and evaporation easily becomes significant due to wicking. The result is a high risk for quick uncontrolled drying of a bed and an unacceptable risk for the creation of
30 channels, cavities and inclusion of air that will disturb the liquid flow characteristics of the bed. For solid phase material comprising a bioactive reactant the risk for irreproducible and irreversible changes in activity is also apparent. There are difficulties in reconstituting fully or partly dried solid phase material in microfluidic

devices to minute well-ordered and homogeneous porous beds/columns having the liquid flow characteristics and binding activity with essentially the same inter-channel and inter-device variation as the wet beds had before drying.

5 These problems are typically more pronounced for hydrophilic and/or water-swellable solid phase material than for hydrophobic that do not swell in water. See figures 2a-b and 3.

Our experience with wet hydrophilic beds implanted the idea that the beds have to be
10 dried under controlled conditions. It still, however, turned out difficult to implement dried solid phase material that could be reconstituted in the desired way to minute porous beds/columns, e.g.

- The solid phase material typically carries a reactant that is sensitive to drying, storage and transportation.
- 15 • The binding of the solute to a porous bed in a microfluidic device may be monitored by spectrometric methods through a detection window associated with the porous bed. The creation of undesired channels, cavities and air inclusions will increase the noise level for detection and thus also reduce sensitivity and reproducibility.
- 20 • During transportation of microfluidic devices that comprises porous beds, there is a significant risk that solid phase material may escape from the microcavity. The risk for losses of dispensed reagents and analyte by reactions with escaped solid phase material at undefined locations within a microchannel structure is apparent. This kind of problem is most severe if the bed is built up of particles.

25

OBJECTS OF THE INVENTION

The objects are to provide improved microfluidic devices that solve the problems discussed above. The objects thus comprise to provide microfluidic devices comprising solid phase material in a dry state that after storage and transportation of
30 the device can be reconstituted to wet beds with essentially the same performance as wet beds of the same solid phase material not having been transformed to the dry state. If the solid phase material comprises an immobilized reactant, its activity, e.g. binding activity such as capacity to bind the solute, shall be essentially unchanged by

transformation to the dry state, storage, transportation and reconstitution. This in particular applies to activity under flow conditions.

The objects include providing methods for manufacturing the devices and use of the
5 devices for separation and/or assay purposes, among others.

DRAWINGS

Figure 1 gives a subgroup (100) of microchannel structures (101a-h) of the microfluidic device utilized in the experimental part.

10 **Figures 2a and b** show a swellable solid phase material in particle form (Superdex™ Peptide, Amersham Biosciences, Uppsala, Sweden) placed in a reaction microcavity (104a-h). In **figure 2a** the particles have been lyophilized. The particles are lumped together and scattered randomly in the reaction microcavity. No packed bed is at hand. In **figure 2b** the solid phase material
15 has been reconstituted to a well-ordered wet porous bed.

Figure 3 shows monodisperse essentially non-swellable and hydrophilic particles packed to a porous bed and lyophilised in a reaction microcavity (104a-h). The bed looked essentially the same after reconstitution (not shown).

20 **Figures 4a and b** show the effect of drying (lyophilization) together with potassium phosphate buffer on the performance of a packed bed of particles to which streptavidin has been immobilized. Fluorescence intensity is given in radial direction through the bed (length of the bed) with the peak typically at the entrance. Flow direction is from the right to the left. Storage for one month at +4°C. The effect is measured in a fluorescence myoglobin immunoassay
25 (below) at four different concentrations of myoglobin and compared with the performance of a bed of the same material that has not been dried (lyophilized) (slurry). The myoglobin concentrations were 4.56 nM (graph 4), 22.8 mM (graph 3), 91.2 (graph 2) and 273.6 (graph 1). **Figure 4a** is after lyophilization and storage together with potassium phosphate. **Figure 4b** is
30 without drying.

Figures 5a-d show the effect of three different drying procedures with a bed-preserving agent (sugar variant, trehalose) on the performance of a packed bed of particles to which streptavidin has been covalently coupled. Storage

and measurement is the same as for figures 4a-b. **Figure 5a** is without drying, **figure 5b** is drying at atmospheric pressure (by wicking), **figure 5c** is vacuum-drying, and **figure 5d** is lyophilization. The myoglobin concentrations for the various graphs are the same as in figures 4a-b.

5 **Figure 6** shows a standard curve for the immunoassay given in the experimental part with myoglobin samples (diluted in PBS with 1% BSA, concentrations of myoglobin 0-274 nM). Solid phase (PS-PheDex-streptavidin in 100 mM trehalose) dried at atmospheric pressure, storage 1 month at +4°C. The y-axis gives fluorescence and the x-axis concentration log.

10

THE INVENTION

It has now been discovered that there are certain compounds and/or combinations of compounds that, when intimately mixed with a solid phase material, will reduce adverse effects of predispensing, drying, storage, transportation, reconstitution etc of

15 solid phase materials intended to be used as minute porous beds in microfluidic devices. These negative effects are for example:

- a) unacceptable formation of channels, cavities, air inclusions etc and/or,
- b) escape of solid phase material from a desired location within a microchannel structure, and/or
- 20 c) reduction of the binding activity of an immobilized reactant, e.g. affinity reactant

A compound or a combination of compounds that reduces/reduce these adverse effects will henceforth be called “bed-preserving agent” or simply “preserver” since they will assist in restoring a dried solid phase material to an efficient wet porous bed.

25 According to the inventive principle a bed-preserving agent is simply included in the liquid phase of a wet solid phase material before drying/dehydration. Drying can take place inside or outside the microfluidic device. By using the proper inlet arrangements (102,103a-h) such as a distribution manifold (106a-h) and or single volume metering units (108a-h) described herein, we have found that the accuracy for the formation of
30 reconstituted wet beds of predetermined volume can be further increased. Inter-channel variations due to drying, storage, transportation and/or reconstitution of preloaded solid phase materials can easily be held at a minimum.

It has also been discovered that common flow control as defined in WO 02075312 (Gyros AB) is beneficial for increasing the accuracy when restoring wet porous bed volumes in parallel in reaction microcavities of at least a subset of microchannel structures of a microfluidic device. Centrifugal force, for instance, is useful for

- 5 improving the yield of efficient porous beds if applied for settling and restoring the beds.

FIRST ASPECT: MICROFLUIDIC DEVICE

This aspect is a microfluidic device that comprises one, two or more microchannel structures (101), each of which comprises a reaction microcavity (104a-h) intended for retaining a solid phase material in the form of a porous bed. The device is characterized in that the reaction microcavity (104a-h) in one, two or more of the microchannel structures (101) comprises a hydrophilic solid phase material in a dry state that comprises a compound or a combination of compounds that act as a bed-preserving agent. These compounds thus secure that an acceptable wet porous bed can be restored after a reconstitution liquid has passed the dry state solid phase material. The bed preserving agent(s) is(are) capable of

- a) stabilizing the solid phase material possibly containing an immobilized reactant (e.g. an affinity reactant) during
- 20 (i) transformation of a wet state of the solid phase material to a dry state, and/or (ii) a subsequent storage and/or transportation, and/or
- b) assisting in the reconstitution of the dry state to a wet porous bed.

The term "acceptable wet porous bed" means that the experimental results from the bed can be used, i.e. the bed is functional. The term "unacceptable" means that the experimental results are discarded. The bed-preserving agent thus increases the probability for obtaining acceptable beds. The use of the principles of the invention may thus assist in increasing the yield of functional beds or microchannel structures on a microfluidic device to become $\geq 70\%$, such $\geq 80\%$ or $\geq 90\%$ or $\geq 95\%$ or $\geq 98\%$

30 % of the total number of beds or microchannel structures of a microfluidic device.

By the term "dry state" is meant that the amount of remaining liquid after drying is $\leq 50\%$, such as $\leq 30\%$ or $\leq 20\%$ or $\leq 10\%$ of the amount of liquid present in the solid

phase material when saturated with the liquid concerned (with no free liquid layer appearing on top of the bed). In many cases this means that the amount of liquid in the solid phase material after drying and/or storage is $\leq 20\%$ (w/w), such as $\leq 10\%$ or $\leq 5\%$. The liquid referred to is typically water.

5

Bed-preserving agents (additives)

The damages of a porous bed during drying/dehydration and storage typically depend on stresses induced during transformation from a wet state to a dry state in the similar manner as for biologically active material. The choice of bed-preserving agent will

10 depend on the conditions for drying, the solid phase material, kind of immobilized reactant etc. The same compound(s) may act as bed-preserving agent for one solid phase material and/or immobilized reactant but negatively affect other combinations. It will thus be extremely important to test individual preserver candidates [either as single compounds or as combination(s) of compounds] and conditions for the

15 transformation to the dry state and/or the conditions for storage and/or reconstitution before a candidate is used for a particular solid phase material. Testing is typically by trial and error and may include

- a) physical inspection of the bed to find undesired channels, cavities and air inclusions, and/or
- 20 b) determination of through flow properties, activity of an immobilized reactant, etc. Determination of the activity of the immobilized reactant/ligand may include determination of i) the activity profile in the flow direction and/or perpendicular to the flow direction (i.e. the distribution of activity in the bed), ii) the total activity of the bed etc, for instance by testing the bed behavior in a standard type of assay or in an
- 25 actual future use of the porous bed. If the immobilized reactant is an affinity reactant that is able to capture a solute, the distribution of the solute in the bed after adsorption (capture) may be used to find abnormal local behavior caused by channels, cavities, air inclusions or local inactivation of the reactant, for instance. The total amount of adsorbed solute may give a total view, e.g. a measure of the mean condition of the
- 30 immobilized reactant after reconstitution. Adsorption in the context of testing is preferably performed under flow conditions, i.e. a liquid containing the solute is allowed to flow through the porous bed. These kinds of testing typically include a comparison with a standard bed and/or standard behavior that may be given by

- a) tabulated values,
- b) preset specifications,
- c) the behavior of a bed prepared from non-lyophilized/non-dried solid phase material of the same kind as the lyophilized/dried solid phase material to be tested,

5 etc.

The substeps during which the risk for damages is most significant are primarily the drying step (dehydration step) and the storage as such. In the case freeze-drying is part of the transformation also the freezing step may cause significant damages. For

10 biologically active material, it is well known that particular stabilizers may be required for each substep. Hence, stabilizers have been termed according to kind of substep during which they are active, e.g. cryostabilisators refer to freezing, lyostabilisators to dehydration/drying and long term stabilisators to storage. See for instance Arakawa et al (Advanced Drug Delivery Reviews 46 (2001) 307-326). In the
15 context of the present invention the analogous categorization is used for bed-preserving agents.

Compounds that assist in the reconstitution of the dry solid phase material to the wet porous bed are called bed-reconstitution agents and are also bed-preserving agents.

20

A bed-preserving agent may be active in relation to at least one up to all of the steps: drying/dehydration, freezing, storage and reconstitution. The efficiency of a particular agent will depend on the conditions for the particular step, solid phase material and/or immobilized reactant to be stabilized.

25

A bed-preserving agent that is useful in the present invention typically is hydrophilic in the sense that it is water-soluble. Many bed-preserving agents thus exhibit one or more heteroatoms selected from oxygen, nitrogen and sulphur, typically with a ratio between the total number of carbon atoms and the total number of oxygen, nitrogen
30 and sulphur atoms which is ≤ 6 , such as ≤ 4 or ≤ 2 .

Typical bed-preserving agents may be found in the group consisting of compounds exhibiting a) carbohydrate structure which also includes sugar alcohol structure, b)

polyhydroxy structure (i.e. organic polyols which also includes polyhydroxy polymers), c) amino acid structure including peptide structure and imino acid structure, d) inorganic salts, e) organic salts in particular carboxylates, f) amine structure including amino acid structure and ammonium structure, h) etc.

5

Suitable compounds with carbohydrate structures may be found amongst sucrose, lactose, glucose, trehalose, maltose, isomaltose, cellobiose, inositol, ethylene glycol, glycerol, sorbitol, xylitol, mannitol, polyethylene glycol possibly substituted in one or both of its end, dextran, maltodextrin, monosaccharides, disaccharides,

10 polysaccharides including oligosaccharides etc. Compounds with carbohydrate structures are typically also polyols.

Suitable polyols may be found amongst polyhydroxy polymers, such as polysaccharides, polyvinylalcohol possibly partially substituted on its hydroxy groups

15 for instance with acetate or lower hydroxy alkyl groups (C₂₋₄), poly (lower hydroxy alkyl (C₂₋₄) acrylate) polymers and corresponding poly methacrylate polymers etc, and monomeric compounds having two or more hydroxy groups. In a typical polyol each hydroxy group is attached directly to an sp³-hybridised carbon.

20 Suitable polymers are typically found amongst polymers that have a plurality of functional groups comprising a heteroatom selected from oxygen and nitrogen. Relevant functional groups are -O(CH₂CH₂O)_n- where n is ≥ 2 such as ≥ 5, amido such as -CONH- or -CONH₂ (where H may be replaced with a suitable hydrophilic organic group), hydroxy (OH), ester (-COOR, where R is a suitable hydrophilic 25 organic group), etc. Specific examples are polyethylene glycol, dextran and other polysaccharides, polyvinylpyrrolidone, polypeptides, the poly acrylate and methacrylate polymers mentioned above, the polyvinyl alcohols mentioned above etc.

The term "polymer" above also includes copolymer in which the specific polymer

30 structure mentioned is a part

Bed-preserving agents that are lyostabilisators are believed to act during the drying/dehydration step by replacing water bound to the solid phase material to be

stabilized. These bed-preserving agents thus primarily are found among compounds that may participate in hydrogen bonding/coordination with the solid phase material. With the present knowledge the most typical candidates for lyostabilization are found amongst polyols (including diols, triols etc), e.g. with a polymeric structure and/or 5 carbohydrate structure (oligomeric is included in polymeric). In the case the solid phase material comprises an immobilised reactant, e.g. with peptide structure, it is believed that the most efficient candidates have carbohydrate structure with preference for disaccharides and found amongst sucrose, lactose, glucose, trehalose, maltose, isomaltose, cellobiose etc.

10

Many times suitable bed-preserving agents, such as lyostabilisators and stabilisators for long term storage are capable of existing in a glassy state in the reaction microcavity possibly in admixture with one or more of the other components that are present in the reaction microcavity.

15

The bed-preserving agents that are present in the dry state of a solid phase material are typically non-volatile. This does not exclude that volatile cryostabilisators are included during lyophilization.

20 Protectants (additives)

The solid phase material that is in a dry state may also contain one or more so-called protectants that inhibit undesired chemical reactions of the solid phase material and/or the immobilized reactant. Suitable protectants are found amongst free radical scavengers, antioxidants, reducing agents etc.

25

Other additives

The solid phase material in a dry state may also contain an appropriate buffer, such as a buffer with non-volatile buffering components, e.g. with at least one or two of the buffering components being anionic, such as in phosphate buffers, citrate buffers etc.

30 Also other buffers may be used. The buffering components typically provide an elevated buffer capacity within an appropriate pH interval of the range of pH 1-13 with preference for the range 3-11. For lyophilized solid phase materials, phosphate buffers, in particular with potassium as counter-ion, are preferred.

Other additives such as one or more antimicrobial agents may also be included, e.g. a bacteriostat, a bacteriocid, a virucid etc.

- 5 A possible bulking agent may also be included as an additive. The bulking agent may have bed-preserving effects on the solid phase material as discussed above for bed preserving agents in general.

Microcavity adherence agents (a kind of bed-preserving agents) cause the solid phase

- 10 material to be retained in a reaction microcavity and therefore assist in restoring a dry state solid phase material to a wet porous bed. This kind of agents acts by causing particles to adhere to each other and/or to the inner walls of a reaction microcavity. Microcavity adherence agents may be found amongst the bed-preserving candidates discussed above, for instance amongst those that exhibit carbohydrate and/or
- 15 polymeric structure.

The various additives (bed preserving agents, buffer substances, protectants, bulking agents etc) are typically present in the solid phase material that is in the dry state in an amount in the interval of 0.0001 - 25 %, such as $\geq 0.001\%$ or $\geq 0.01\%$ or $\geq 0.1\%$

- 20 and/or $\leq 10\%$ or $\leq 1\%$. These intervals apply to each individual additive as well as to the total amount of additive with the proviso that the total amount should not exceed the upper limit of an interval. The determination of optimal ranges of efficient amounts and sufficient bed-preserving effects of individual bed-preserving agents needs experimental testing as discussed above. The %-figures refer to the weight of
- 25 the additive(s) relative to the total weight of solid phase material in the dry state.

Additives (stabilisators, buffer substances, protectants, antimicrobials and/or bulking agents) are typically soluble in aqueous media so that they easily can be removed from the reconstituted porous bed, for instance by transporting liquid through the

- 30 reconstituted wet bed (washing).

Reaction microcavity (104a-h) and the solid phase material.

The reaction microcavity (104a-h) is defined as the part of a microchannel structure (101a-h) in which the solid phase is present. This means that for solid phases in the form of porous beds, the bed volume and the reaction microcavity (104a-h) will 5 coincide and have the same volume. If the solid phase is the inner wall of a microconduit, the reaction microcavity (104a-h) is defined as the volume between the most upstream and the most downstream end of the solid phase.

The reaction microcavity (104a-h) is typically a straight or bent microconduit that 10 may or may not be continuously widening and/or narrowing. On the same device all reaction microcavities typically have essentially the same shape and/or size. In a microfluidic device that comprises reaction microcavities according to the invention that differ in shape and/or size, the reaction microcavities/microchannel structures (104a-h/101a-h) may be divided into groups where each group contains reaction 15 microcavities that are not present in any of the other groups. Each group may be placed in a subarea of the device that is separate from the subareas of other groups.

The reaction microcavity (104a-h) has at least one cross-sectional dimension that is \leq 1,000 μm , such as $\leq 500 \mu\text{m}$ or $\leq 200 \mu\text{m}$ (depth and/or width). The smallest cross- 20 sectional dimension is typically $\geq 5 \mu\text{m}$ such as $\geq 25 \mu\text{m}$ or $\geq 50 \mu\text{m}$. The total volume of the reaction microcavity is typically in the nl-range, such as $\leq 5,000 \text{ nl}$, such as 1,000 nl or $\leq 500 \text{ nl} \leq 100 \text{ nl}$ or $\leq 50 \text{ nl}$ or $\leq 25 \text{ nl}$.

The porous bed is a) a population of porous or non-porous particles, or b) a porous 25 monolith.

A monolithic bed may be in the form of a porous membrane or a porous plug.

The term "porous particles" have the same meaning as in WO 02075312 (Gyros AB).

30

Suitable particles are spherical or spheroidal (beaded) or non-spherical. Suitable mean diameters for particles used as solid phases are typically found in the interval of 1-100 μm with preference for mean diameters that are $\geq 5 \mu\text{m}$, such as $\geq 10 \mu\text{m}$ or $\geq 15 \mu\text{m}$

and/or $\leq 50 \mu\text{m}$. Also smaller particles can be used, for instance with mean diameters down to $0.1 \mu\text{m}$. The design of outlet end (111a-h) of the reaction microcavity (104a-h) and the particles should match each other so that the particles can be retained in the reaction microcavity (104a-h). Certain kinds of particles, in particular particles of 5 colloidal dimension, may agglomerate. In these cases the size of the agglomerate should be in the intervals given even if the agglomerating particles as such are smaller. See for instance WO 02075312 (Gyros AB). Diameters refer to the "hydrodynamic" diameters.

10 Particles to be used may be monodisperse (monosized) or polydisperse (polysized) in the same meaning as in WO 02075312 (Gyros AB).

The solid phase material may or may not be transparent.

15 The base material of a solid phase may be made of inorganic and/or organic material. Typical inorganic materials comprise glass and typical organic materials comprise organic polymers. Polymeric materials comprise inorganic polymers, such as glass and silicone rubber, and organic polymers that may be of synthetic or biological origin (biopolymers). The term biopolymer includes semi-synthetic polymers in 20 which there is a polymer backbone derived from a native biopolymer. Typical synthetic organic polymers are cross-linked and are often obtained by the polymerisation of monomers comprising polymerisable carbon-carbon double bonds. Examples of suitable monomers are hydroxy alkyl acrylates and corresponding methacrylates, acryl amides and methacrylamides, vinyl and styryl ethers, alkene 25 substituted polyhydroxy polymers, styrene, etc. Typical biopolymers may or may not be cross-linked. In most cases they exhibit a carbohydrate structure, e.g. agarose, dextran, starch etc.

30 The term "hydrophilic" in the context of a porous bed contemplates a sufficient wettability of the surfaces of the pores for water to be spread by capillarity all throughout the bed when in contact with excess water (absorption). The expression also means that the inner surfaces of the bed that is in contact with water during the absorption shall expose a plurality of polar functional groups which each has a

heteroatom selected amongst oxygen and nitrogen, for instance. Appropriate functional groups can be selected amongst hydroxy groups, ethylene oxide groups (-X-[CH₂CH₂O]_n where n is an integer > 1 and X is nitrogen or oxygen), amino groups, amide groups, ester groups, carboxy groups, sulphone groups etc, with

5 preference for those groups that are essentially uncharged independent of pH, for instance within the interval of 2-12. For solid phase materials in particle form this means that at least the outer surfaces of the particles have to exhibit polar functional groups. The hydrophilic functional groups may be present on or be a part of so called extender arms (tentacles).

10

If the base material of a solid phase material is hydrophobic or not sufficiently hydrophilic, e.g. is based on a styrene (co)polymer, the surfaces that are to be in contact with an aqueous liquid may be hydrophilized. Typical protocols comprise coating with a compound or mixture of compounds exhibiting polar functional groups

15 of the same type as discussed above, treatment by an oxygen plasma etc.

The solid phase material in a dry state may be swellable when contacted with the reconstitution liquid. Swellable materials are likely to be more prone to give problems related to (a) shrinkage/swelling, and inhomogeneous packing and/or through flow

20 after reconstitution, and/or (b) escape of dry particles during storage and transportation. The term "swellable" in this context means an increase in volume of the material (particles as such or a monolith) can be detected when the material in the dry state (as defined above) is contacted with the reconstitution liquid (that may be aqueous such as water). The increase in volume may for instance be ≥ 10 or ≥ 75 % of
25 the volume of the material in a dry state. Solid phase materials that are not swellable according to this definition are considered non-swellable..

The solid phase material may be rigid or elastic.

30 The solid phase material may or may not contain an immobilized reactant that is capable of participating in an organic, an inorganic, a biochemical reaction etc with a solute. Depending on the circumstances and the kind of reactant and solute, the interaction between the immobilized reactant and the solute may be part of a

separation process, a catalytic reaction, a solid phase synthesis, a solid phase derivatization etc.

The immobilized reactant will now be illustrated with an affinity reactant that is an 5 affinity counterpart (AC_S) to a solute (S) and capable of forming an affinity complex (AC_S-S) with the solute. Affinity bonds typically are based on: (a) electrostatic interactions, (b) hydrophobic interactions, (c) electron-donor acceptor interactions, and/or (d) bioaffinity binding.

10 Bioaffinity binding typically is complex and comprises a combination of interactions, such as (a)-(c) above.

An immobilized affinity counterpart (AC_S) may thus:

(a) be electrically charged or chargeable, i.e. contains positively charged nitrogen 15 (e.g. primary, secondary, tertiary or quaternary ammonium groups, and amidinium groups) and/or negatively charged groups (e.g. carboxylate groups, phosphate groups, phosphonate groups, sulphate groups and sulphonate groups); and/or
(b) comprise one or more hydrocarbyl groups and other hydrophobic groups; and/or
(c) comprise one or more heteroatoms (O,S,N), possibly linked to hydrogen and/or 20 sp-, sp²- and/or sp³-hybridised carbon, and/or
(d) comprise a combination of features (a)-(c).

A bioaffinity reactant/ligand is a member of a bioaffinity pair. Typical bioaffinity pairs are a) antigen/hapten and an antibody, b) complementary nucleic acids, c) 25 immunoglobulin-binding protein and immunoglobulin (for instance IgG or an Fc-part thereof and protein A or G), d) lectin and the corresponding carbohydrate, e) biotin and (strept)avidin, e) members of an enzymatic system (enzyme-substrate, enzyme-cofactor, enzyme-inhibitor etc), f) an IMAC group and an amino acid sequence containing histidyl and/or cysteinyl and/or phosphorylated residues (i.e. an IMAC 30 motif), etc. Antibody includes antigen binding fragments and mimetics of antibodies. The term "bioaffinity pair" includes also affinity pairs in which one or both of the members are synthetic, for instance mimicking one or both of the members of a native bioaffinity pair. The term IMAC stands for an immobilized metal chelate.

The term "affinity reactant" also includes a reactant that is capable of reversible covalent binding, for instance by disulfide formation. This kind of reactants typically exhibits a HS- or a $-S-SO_n-$ group ($n = 0, 1$ or 2 , free valences bind to carbon). See

5 US 5,887,997 (Batista), US 4,175,073 (Axén et al), and 4,563,304 (Axén et al).

The immobilized reactant/ligand (affinity reactant) may also be a catalytic system or a member of a catalytic system, such as a catalyst, a cocatalyst, a cofactor, a substrate or cosubstrate, an inhibitor, a promotor etc. For enzymatic systems the corresponding

10 members are enzyme, cocatalyst, cofactor, coenzyme, substrate, cosubstrate etc. The term "catalytic system" also includes linked catalytic systems, for instance a series of systems in which the product of the first system is the substrate of the second catalytic system etc and whole biological cells or a part of such cells.

15 The immobilized affinity reactant (AC_S) should be selected to have the appropriate selectivity and specificity for interacting with the solute of interest to the solid phase material in relation to an intended application. General methods and criteria for the proper selection of affinity reactants and reaction conditions are well known in the field.

20

The affinity constant ($K_{S-AC} = [S][AC_S]/[S--AC_S]$) for the formation of the complex comprising the immobilized affinity reactant (AC_S) and the solute (S) is an important criterion for optimizing an application and varies depending on application. For affinity assays the affinity constant is typically $\leq 10^{-8}$ mole/l or $\leq 10^{-9}$ mole/l. This

25 kind of assays typically includes that the solute is reacted with immobilized AC_S under flow conditions and related to the amount of an analyte in an animal or biological sample (animal or biological sample include samples from mammals, such as human and other animal patients, and from experimental animals). This does not exclude that affinity counterparts having weaker affinities may be used for this kind of

30 samples, other samples and affinity assays, and other applications. Thus depending on application the affinity constant may be relatively large, such as up to 10^{-3} mole/l or up to 10^{-4} mole/l or up to 10^{-5} or up to 10^{-7} mole/l, or relatively low, such as less than 10^{-8} mole/l or less than 10^{-11} mole/l.

The techniques for immobilization of a reactant/ligand may be selected amongst techniques that are commonly known in the field. The linkage to the solid phase material may thus be via covalent bonds, affinity bonds (for instance biospecific affinity bonds), physical adsorption etc.

Immobilization via affinity bonds may utilize an immobilizing affinity pair in which one of the members (immobilized ligand or L) is firmly attached to the solid phase material, for instance covalently. The other member (immobilizing binder, B) of the pair is used as a conjugate (immobilizing conjugate) comprising binder B and the affinity counterpart AC_S to the solute S. Examples of immobilizing affinity pairs are a) streptavidin/avidin/ neutravidin and a biotinylated reactant (or vice versa), b) antibody and a hapteneylated reactant (or vice versa), c) an IMAC group and an amino acid sequence containing histidyl and/or cysteinyl and/or phosphorylated residues (i.e. an IMAC motif) linked to or being a part of a reactant, etc.

The term "conjugate" primarily refers to covalent conjugates, such as chemical conjugates and recombinantly produced conjugates (where both the moieties have peptide structure). The term also includes so-called native conjugates, i.e. affinity reactants exhibiting two binding sites that are spaced apart from each other, with affinity directed towards two different molecular entities, for instance a native antibody that comprises species and class-specific determinants on one side (= one part) of the molecule and antigen/hapten-binding sites on another side (= one part).
It is believed that it is advantageous that the immobilized ligand L has two or more binding sites for the immobilizing binder B, and/or the immobilizing binder B has one, two or more binding sites for the ligand L (or vice versa).

Preferred immobilizing affinity pairs (L and B) typically have affinity constants (K_{L-B}) = $[L][B]/[L-B]$) that are at most equal to or ≤ 10 times or 10^2 times or $\leq 10^3$ times larger than the corresponding affinity constant for streptavidin and biotin. This typically will mean affinity constants that roughly are $\leq 10^{-13}$ mole/l, $\leq 10^{-12}$ mole/l, $\leq 10^{-11}$ mole/l and $\leq 10^{-10}$ mole/l, respectively. The preference is to select L and B

amongst biotin-binding compounds and streptavidin-binding compounds, respectively, or vice versa.

The affinity constants discussed above refer to values obtained by a biosensor (surface plasmon resonance) from Biacore (Uppsala, Sweden), i.e. with the affinity reactant (AC_S and L) immobilized to a dextran-coated gold surface.

At least one of the members of an affinity pair, in particular a bioaffinity pair, to be used in the present invention typically exhibits a structure selected amongst: a) amino acid structure including peptide structure such as poly and oligopeptide structure, b) carbohydrate structure, c) nucleotide structure including nucleic acid structure, d) lipid structure such as steroid structure, triglyceride structure etc. The term affinity pair in this context refers to the immobilizing affinity pair (L and B), the immobilized affinity reactant and the solute (AC_S and S) and other affinity pairs that may be used.

15

The solid phase material that is in a dry state may alternatively be in activated form. In other words ready for direct covalent immobilization by reaction with a functional group of a desired reactant. The functional group that can be used on the desired reactant is typically selected amongst electrophilic and nucleophilic groups and 20 depends on whether or not the activated group is nucleophilic or electrophilic, respectively. Examples of functional groups that may be used are amino groups and other groups comprising substituted or unsubstituted -NH₂, carboxy groups (-COOH/-COO⁻), hydroxy groups, thiol groups, keto groups etc.

25 Other features of the microfluidic device

A microchannel structure (101a-h) of a microfluidic device comprises functional parts that permit the full protocol of an experiment to be performed within the structure. A microchannel structure (101a-h) of the microfluidic device thus may comprise one, two, three or more functional parts selected among: a) inlet arrangement (102,103a-h) 30 comprising for instance an inlet port/inlet opening (105a-b,107a-h), possibly together with a volume-metering unit (106a-h,108a-h), b) microconduits for liquid transport, c) reaction microcavity (104a-h); d) mixing microcavity/unit; e) unit for separating particulate matters from liquids (may be present in the inlet arrangement), f) unit for

separating dissolved or suspended components in the sample from each other, for instance by capillary electrophoresis, chromatography and the like; g) detection microcavity; h) waste conduit/microcavity (112,115a-h); i) valve (109a-h,110a-h); j) vent (116a-i) to ambient atmosphere; etc. A functional part may have more than one 5 functionality, e.g. reaction microcavity (104a-h) and a detection microcavity may coincide. Various kinds of functional units in microfluidic devices have been described by Gyros AB/Amersham Pharmacia Biotech AB: WO 99055827, WO 99058245, WO 02074438, WO 02075312, WO 03018198 (US 20030044322), WO 03034598, SE 03026507 (SE 04000717, US SN 60/508,508), SE 03015393 (US SN 10 60/472,924) and by Tecan/Gamera Biosciences: WO 01087487, WO 01087486, WO 00079285, WO 00078455, WO 00069560, WO 98007019, WO 98053311.

In advantageous forms a reaction microcavity (104a-h) intended for a hydrophilic porous bed is connected to one or more inlet arrangements (upstream direction) 15 (102,103a-h), each of which comprises an inlet port (105a-b,107a-h) and at least one volume-metering unit (106a-h,108a-h). In one advantageous variant, there is one separate inlet arrangement (103a-h) per microchannel structure (101a-h) and reaction microcavity (104a-h) intended to contain the solid phase material. In another advantageous variant, the inlet arrangement (102) is common to all or a subset (100) 20 of microchannel structures (101a-h) and reaction microcavities (104a-h) intended to contain the solid phase material and comprises a common inlet port (105a-b) and a distribution manifold with one volume-metering unit (106a-h) for each microchannel structure/reaction microcavity (101a-h/104a-h) of the subset (100). In both variants, each of the volume-metering units (106a-h,108a-h) in turn is communicating with 25 downstream parts of its microchannel structure (101a-h), e.g. the reaction microcavity (104a-h). Microchannel structures linked together by a common inlet arrangement (102) and/or common distribution manifold define a group or subset (100) of microchannel structures. Each volume-metering unit (106a-h,108a-h) typically has a valve (109a-h,110a-h) at its outlet end. This valve is typically passive, for instance 30 utilizing a change in chemical surface characteristics at the outlet end, such as a boundary between a hydrophilic and hydrophobic surface (hydrophobic surface break) (WO 99058245 (Amersham Pharmacia Biotech AB)) and/or in geometric/physical surface characteristics (WO 98007019 (Gamera)).

Typical inlet arrangements with inlet ports, volume-metering units, distribution manifolds, valves etc have been presented in WO 02074438 (Gyros AB), WO 02075312 (Gyros AB), WO 02075775 (Gyros AB) and WO 02075776 (Gyros AB).

5

The microfluidic device may also comprise other common microchannels/micro conduits connecting different microchannel structures. Common channels including their various parts such as inlet ports, outlet ports, vents, etc., are considered part of each of the microchannel structures they are communicating with.

10

Common microchannels make it possible to construe microfluidic devices in which the microchannel structures form networks. See for instance US 6,479,299 (Caliper).

Each microchannel structure has at least one inlet opening (105a-b,107a-h) for liquids 15 and at least one outlet opening for excess of air (vents) (116a-i) and possibly also for liquids (circles in the waste channel (112)).

The microfluidic device may also comprise microchannel structures that have no reaction microcavity for retaining a solid phase material according to the invention.

20

The microfluidic device contains a plurality of microchannel structures/device intended to contain the solid phase according to the invention. Plurality in this context means two, three or more microchannel structures and typically is ≥ 10 , e.g. ≥ 25 or ≥ 90 or ≥ 180 or ≥ 270 or ≥ 360 . As discussed above the microcannel structures of a 25 device may be divided in groups or subsets (100), each of which may for instance be defined by the size and/or shape of the reaction microcavity, by a common microchannel (102,112), such as a common inlet arrangement (102) with manifold, common waste channel (112) etc. The number of microchannel structures in a group or subset is typically in the interval 1-99 %, such as 5-50 % or 5-25 % or 10-50%, of 30 the total number of microchannel structures of the device. This typically means that each group typically comprises from 3-15 or 3-25 or 3-50 microchannel structures. Each group may be located to a particular area of the device.

Different principles may be utilized for transporting the liquid within the microfluidic device/microchannel structures between two or more of the functional parts described above. Inertia force may be used, for instance by spinning the disc as discussed in the subsequent paragraph. Other useful forces are capillary forces, electrokinetic forces, 5 non-electrokinetic forces such as capillary forces, hydrostatic pressure *etc.*

The microfluidic device typically is in the form of a disc. The preferred formats have an axis of symmetry (C_n) that is perpendicular to or coincides with the disc plane, where n is an integer $\geq 2, 3, 4$ or 5 , preferably ∞ (C_∞). In other words the disc may be 10 rectangular, such as square-shaped and other polygonal forms but is preferably circular. Once the proper disc format has been selected centrifugal force may be used for driving liquid flow. Spinning the device around a spin axis that typically is perpendicular or parallel to the disc plane may create the necessary centrifugal force. In the most obvious variants at the priority date, the spin axis coincides with the 15 above-mentioned axis of symmetry.

For preferred centrifugal-based variants, each microchannel structure comprises one upstream section that is at a shorter radial distance than a downstream section (from the spin axis). The reaction microcavity intended for the porous bed is typically at a 20 radial position intermediary to the two sections.

If centrifugal force is used for the formation and/or reconstitution of a particle bed and/or for driving liquid flow through the bed, the reaction microcavity is typically oriented with the flow direction radially outwards from the spin axis.

25

The preferred devices are typically disc-shaped with sizes and/or forms similar to the conventional CD-format, e.g. sizes that are in the interval from 10% up to 300 % of a circular disc with the conventional CD-radii (12 cm). The upper and/or lower sides of the disc may or may not be planar.

30

Microchannels/microcavities of a microfluidic devices may be manufactured from an essentially planar substrate surface that exhibits the channels/cavities in uncovered form that in a subsequent step are covered by another essentially planar substrate (lid).

See WO 91016966 (Pharmacia Biotech AB) and WO 01054810 (Gyros AB). Both substrates are preferably fabricated from plastic material, e.g. plastic polymeric material.

5 The fouling activity and hydrophilicity of inner surfaces should be balanced in relation to the application. See for instance WO 0147637 (Gyros AB).

The terms "wettable" (hydrophilic) and "non-wettable" (hydrophobic) contemplate that a surface has a water contact angle $\leq 90^\circ$ or $\geq 90^\circ$, respectively. In order to

10 facilitate efficient transport of a liquid between different functional parts, inner surfaces of the individual parts should primarily be wettable, preferably with a contact angle $\leq 60^\circ$ such as $\leq 50^\circ$ or $\leq 40^\circ$ or $\leq 30^\circ$ or $\leq 20^\circ$. These wettability values apply for at least one, two, three or four of the inner walls of a microconduit. In case one or more of the inner walls have a higher water contact angle this can be compensated for
15 by a lower water contact angle for the inner wall(s). The wettability, in particular in inlet arrangements should be adapted such that an aqueous liquid will be able to fill up an intended microcavity by capillarity (self suction) once the liquid has started to enter the cavity. A hydrophilic inner surface in a microchannel structure may comprise one or more local hydrophobic surface breaks in a hydrophilic inner wall,
20 for instance for introducing a passive valve, an anti-wicking means, a vent solely function as a vent to ambient atmosphere etc (rectangles in figure 1). See for instance WO 99058245 (Gyros AB) and WO 02074438 (Gyros AB).

Contact angles refer to values at the temperature of use, typically $+25^\circ\text{C}$, are static

25 and can be measured by the method illustrated in WO 00056808 (Gyros AB) and WO 01047637 (Gyros AB).

**SECOND ASPECT: METHOD FOR THE TRANSFORMATION OF A PLURALITY OF WET POROUS BEDS TO A DRY/DEHYDRATED STATE THAT POSSIBLY IS RECONSTITUTED TO
30 A PLURALITY OF WET POROUS BEDS .**

This aspect is a method as defined in the heading of this section. The method is characterized in comprising the steps of:

- i) providing a microfluidic device comprising a plurality of microchannel structures (101a-h) each of which comprises a reaction microcavity (104a-h) containing a hydrophilic porous bed saturated with a liquid containing a bed-preserving agent,
- 5 ii) transforming the bed in each reaction microcavity (104a-h) to a solid phase material that is in a dry and/or dehydrated state while being retained in the reaction microcavity,
- iii) possibly reconstituting in each reaction microcavity (104a-h) the solid phase material obtained in step ii) to the wet porous beds.

10

This aspect also concerns a method for reducing the inter-channel variation in a microfluidic device with respect to performance of reconstituted porous beds.

The solid phase material may or may not exhibit a reactant that can interact with a 15 solute in a subsequently introduced liquid aliquot. Various characteristics are discussed below and elsewhere in this specification.

Step (iii) is preferably carried out under flow conditions, for instance with residence time and flow rates through the bed as discussed for the third aspect of the invention.

20

Porous particle beds can be created by flowing a dispersion of particles through all or one or more subsets (100) of the reaction microcavities (104a-h) of the microfluidic device. The particles will then settle and form a porous bed at the outlet end (111a-h) of each microcavity (104a-h). Bed formation may be facilitated by the use of gravity 25 and/or the use of centrifugal force, the latter preferably acting along the flow direction of each reaction microcavity (104a-h). The desired additives as discussed above are present in the liquid dispersion and/or introduced by passing a liquid containing the additives through the bed after it has been formed. The microfluidic device together with the beds saturated with a liquid containing the additives is saved until 30 transformation to the dry state.

A porous monolithic bed is typically introduced during the manufacture of the device, for instance

- a) by polymerization, or
- b) by placing ready-made porous monoliths

in each of at least one subset (100) of the reaction microcavities (104a-h) of the microfluidic device.

5

In alternative a) the preferred variant is to carry out the polymerization with the reaction microcavity (104a-h) and the corresponding microchannel structure (101a-h) in an enclosed form. In alternative b) the preferred variant is to insert the monolith while at least the reaction microcavity (104a-h) is uncovered (and remaining part of

10 the microchannel structure (101a-h) is covered). After introduction of the porous bed and if needed enclosing the microcavity, the beds are saturated with a solution comprising the additives discussed above and saved until transformation to the dry state.

15 Transformation of the beds to the dry state may be accomplished by removing the liquid under subatmospheric pressure, for instance below and/or above the freezing point of the liquid they are saturated with. Removal under subatmospheric pressure and below the freezing point typically means lyophilization. Alternatively liquid is removed from the settled dispersion under the pressure of ambient atmosphere with or

20 without warming.

In the case the device is designed for driving liquid transport by centrifugal force so called spin-drying may be employed. See description of figure 1 in the experimental part.

25

Due to the small dimensions and inner edges between the walls around the reaction microcavity wicking will be an important factor in drying/dehydration/evaporation, in particular at atmospheric pressure.

30 The reconstitution of the wet porous beds means that a reconstitution liquid is allowed to flow through each of the reaction microcavities containing solid phase material in a dry state. See the experimental part.

An important tool for treating the solid phase material equally and/or in parallel in several structures is to provide each microchannel structure (101a-h) with an inlet arrangement (102,103a-h) that in preferred variants is common (102) to a group/subset (100) of microchannel structures/reaction microcavities (101a-h/104a-h)

5 as discussed for the first aspect. Thus this kind of design will facilitate parallel dispensation of solid phase material as well as parallel reconstitution and conditioning of porous beds. In order to accomplish the best benefits of the invention it is thereby important to provide inner surfaces of at least the inlet arrangements (102,103a-h), distribution manifold, and/or individual volume-metering units (106a-h/108a-h) with

10 hydrophilic surface characteristics within the limits discussed elsewhere in this specification and the outlet of each volume-metering unit (106a-h,108a-h) with a valve function (109a-h,110a-h) that preferably is passive in the sense that it is without movable parts, for instance in the form of a local hydrophobic surface break.

15 **15 THIRD ASPECT OF THE INVENTION. THE USE OF THE DEVICE.**

The use of the innovative microfluidic devices comprises in general terms the steps of:

(i) providing a microfluidic device according to the first aspect of the invention;

20 (ii) reconstituting the solid phase material that is in the dry state to a wet porous bed in a predetermined number of the microchannel structures /reaction microcavities (101a-h/104a-h), preferably under flow conditions,

(iii) providing a liquid containing a solute (S') in a position that is upstream to said wet porous bed in one or more of the microchannel structures (101a-

25 (iv) containing the wet porous bed,

(iv) transporting the liquid through said wet bed in at least one of said one or more microchannel structures (101a-h).

Steps (i) and (ii)

30 These steps are according to the first and second aspects of the invention.

Steps (iii) and (iv)

The solute (S') is typically capable of interacting with the wet porous bed.

Step (iii) comprises that the solute (S') is formed within the device/microchannel structure or is dispensed to the microchannel structure. If applicable, formation is typically in a position upstream or within the wet porous bed/reaction microcavity

5 (104a-h). Dispensing is typically to an inlet port (105a-b,107a-h) at a position upstream the porous bed/reaction microcavity (104a-h).

Steps (iii) and (iv) are performed in order to allow for an interaction between the solute (S') and the porous bed to take place. As mentioned in the introductory part, the

10 steps may be part of (a) a separation method, and/or (b) a catalytic reaction, (c) a solid phase synthesis, and/or (d) a derivatization of the solid phase material/porous bed.

Separation comprises among others:

i) Capturing, i.e. the porous bed exhibits an affinity structure (affinity ligand, affinity reactant) ($AC's'$) with binding ability for the solute (S'). When a liquid containing the solute (S') passes through the bed then the solute (S') will be captured/bound to the porous bed via $AC's'$. After passage through the porous bed the liquid will be devoid or have a reduced amount of solute (S'). $AC's'$ and S' will correspond to AC_S and S , respectively, discussed above.

15 ii) Size exclusion, i.e. the porous bed is more prone to retain smaller molecules compared to larger molecules. The solute (S') will be retarded relative to the movement of a liquid front and therefore initially enriched in the wet porous bed.

20 iii) electrophoresis, i.e. the porous bed functions as anti-convection and/or anti-diffusion means.

25

For many separation protocols, a combination of two or more of capturing, size exclusion, electrophoresis etc is utilized either in consecutive beds or in the same bed.

The separation may be part of a purification or enrichment protocol for a solute that is

30 present in the liquid. The solute that is separated from the liquid may be a contaminant or the entity to be purified, enriched etc. The separation may also be part of a synthetic protocol, preparative protocol, a cell based assay, various kinds of affinity assays including nucleic acid assays, immunoassays, enzyme assays etc.

An affinity assay utilizing a capturing step for binding a solute to a solid phase material typically contemplates characterization of a reaction variable involved in an affinity reaction of the assay. Reaction variables in this context are mainly of two

5 types: 1) variables related to affinity reactants, and 2) reaction conditions. Variables of type 1 comprises two main subgroups a) amounts including presence and/or absence, concentration, relative amounts, activity such as binding activity and enzyme activity, etc, and b) properties of affinity reactants including affinity as such, e.g. affinity constants, specificities etc. See WO 02075312 (Gyros AB). The molecular

10 entity for which a reaction variable of type 1 is characterized is called an analyte.

Catalytic reactions in the context of the present invention comprises that the solid phase material exhibits one or more immobilized members (e.g. affinity structure, affinity ligand, affinity reactant) of the catalytic system utilized, while other members

15 of the same system are solutes. The catalytic reaction comprises formation of an affinity complex between the immobilized member (affinity structure, affinity ligand, affinity reactant) and at least one of the solute members. At least one of the members corresponds to the substrate for the catalytic system. The reaction results in a product that typically has a different chemical composition and/or structure compared to the

20 substrate. The product may or may not become immobilized to the bed during the reaction.

The term "catalytic system" includes single catalytic system and more complex variants comprising a series of linked single enzyme systems, whole cells, cell parts

25 exhibiting enzymatic activity etc. The bed may function as a catalytic reactor, such as an enzyme reactor.

The step during which interaction with the solute occurs may be part of a catalytic assay, such as an enzyme assay, for characterizing one or more members of the

30 catalytic system or other reaction variables (e.g. reaction conditions). The assay may be for determining the activity of a particular catalyst, substrate, co-substrate, cofactor, co-catalyst etc in a liquid sample. The molecular entity/entities

corresponding to the activity to be determined is/are called analyte/analytes. See for instance WO 03093802 (Gyros AB).

In the context of assays, the term analyte includes the entity to be characterized in an 5 original sample as well as analyte-derived entities formed during the assay and being related quantitatively to the analyte in the original sample. The solute discussed above may be the original analyte or an analyte-derived entity.

Solid phase synthesis includes for instance polymer synthesis, such as oligopeptide 10 and oligonucleotide synthesis and synthesis of other small molecules on a solid phase material. The immobilized reactant used in polymer synthesis, for instance, may exhibit the structure of the corresponding monomer, such as nucleotide, carbohydrate, amino acid structure, and mimetics of these structures. Synthesis of libraries of immobilized members of combinatorial libraries is also included. Such members have 15 relatively low molecular weights (e.g. < 10,000 dalton including a possible spacer to a polymeric backbone).

Solid phase derivatization in the context of the present invention in most instances has as the goal to introduce an immobilized reactant or an activated functional group 20 on the wet porous bed. Solid phase derivatization thus includes introduction of reactive structures or groups that permit immobilization of a desired reactant via covalent bonds or via affinity/adsorptive bonds. Thus starting from a wet porous bed that exposes an immobilized ligand L and passing a liquid containing an immobilizing conjugate (B-R = S'; B is an immobilizing affinity binder B and R is the reactant R to 25 be immobilized), the reactant R will be firmly attached and exposed on the porous bed as discussed above for L and the immobilizing conjugate B-AC_S. If R is an affinity counterpart AC_S to a solute S (B-R = B-AC_S) the resulting porous bed can be used as discussed above for capturing/separating the solute S from a liquid containing the solute S.

30

The transport during step (iv) comprises that the liquid is continuously flowing through the porous bed or that the liquid transport is halted when the liquid is within the bed. The interaction between a reactant immobilized on the bed and a solute can

thus take place under flow condition or under static conditions, respectively. We have previously found that more information may be gained about reaction variables in affinity reactions if this kind of reactions is taking place under flow conditions (WO 02075312 (Gyros AB). The flow rate and/or residence time may for instance be

5 adjusted such that the amount of solute (S) becoming bound to an affinity counterpart (AC_S) immobilized to the solid phase will reflect the actual reaction rate or affinity between an immobilized affinity reactant, typically AC_S, and a solute, typically solute S, with a minimum of perturbation by diffusion (non-diffusion limiting conditions). This also applies to the present invention but does not exclude that for applications

10 where the primary interest is the total amount of bound/captured solute, capturing under flow conditions utilizing either diffusion limiting or non-diffusion limiting conditions can be used. The appropriate flow rate through the porous bed thus depends on a number of factors, e.g. the immobilized reactant and the solute and their sizes, the volume of the reaction microcavity, the porous bed including the solid phase

15 material etc. Typically the flow rate should give a residence time of ≥ 0.010 seconds such as ≥ 0.050 sec or ≥ 0.1 sec with an upper limit that typically is below 2 hours such as below 1 hour. Illustrative flow rates are within 0.01-1000 nl/sec, such as 0.01-100 nl/sec and more typically 0.1 - 10 nl/sec. These flow rate intervals may be useful for bed volumes in the range of 1-200 nl, such as 1-50 nl or 1-25 nl. Residence time

20 refers to the time it takes for a liquid aliquot to be in contact with the solid phase/porous bed in the reaction microcavity. These intervals are also applicable to other uses of the innovative microfluidic devices including separation, catalytic assays, solid phase synthesis, solid phase derivatization etc.

25 BEST MODE

The best mode of the invention at the filing of this application is given in the experimental part and encompasses the solid phase materials shown, trehalose as bed-preserving agent, potassium phosphate as additional additive (buffer), and a microfluidic device with the microchannel structures given in figure 1.

The microfluidic device used for the experiments was circular and of the same dimension as a conventional CD (compact disc). This microfluidic device will further on be called CD. The CD contained 14 groups (100) of 8 microchannel structures

5 (101a-h) arranged in an annular zone around the center (spin axis) of the disc with a common waste channel (112) for each group close to the periphery. A group (100) of 8 microchannel structures (101a-h) is shown in figure 1 and is similar to and function in the same manner as the group of microchannel structures illustrated in figures 1-2 in WO 02075312 (Gyros AB) and the corresponding figures in WO 03024548 (US 10 20030054563) (Gyros AB) and WO 03024598 (US 20030053934) (Gyros AB). The dimensions are essentially of the same size as in these earlier patent applications.

Each subset (100) comprises eight microchannel structures (101a-h) with one common inlet arrangement (102), one separate inlet arrangement (103a-h) per

15 microchannel structure, and one reaction microcavity (104a-h) per microchannel structure. The common inlet arrangement comprises a) two common inlet ports (105a-b) that also will function as outlet ports for excess liquid, and b) one volume-metering unit (106a-h) for each microchannel structure (101a-h). The volume-metering units (106a-h) will function as a distribution manifold for the downstream parts of the 20 microchannel structures. Each of the separate inlet arrangements (103a-h) is part of only one microchannel structure and comprises an inlet port (107a-h) and a volume-metering unit (108a-h). Between each volume-metering unit (106a-h, 108a-h) and their downstream parts, respectively, there is a valve function (109a-h, 110a-h), preferably passive. A reaction microcavity (104a-h) of a microchannel structure 25 (101a-h) is located downstream both the common inlet arrangement (102) and a separate inlet arrangement (103a-h) of a microchannel structure (101a-h). At the outlet end (111a-h) of each reaction microcavity, the depth is lowered from 100 μm to 10 μm in two steps to prevent particles from escaping the reaction microcavity. Each reaction microcavity (104a-h) is in the downstream direction connected to an outlet 30 microconduit (113a-h) that in figure 1 is illustrated as an outward bent and has an outlet end (114a-h) connected to a waste function (115a-h). At the periphery there is a common waste channel (112). Vents (116a-i, hydrophobic breaks) together with the

valves (109a-h, hydrophobic breaks) define the volume of the liquid aliquots to be distributed downstream from each the volume-metering unit (106a-h).

By applying the appropriate volume of aqueous liquid to the inlet port of an inlet arrangement, capillarity will fill the volume-metering unit(s) connected to the inlet port with liquid. By spinning the disc around its center, liquid can be forced to pass the valve (109a-h,110a-h) between a volume-metering unit and downstream parts.

Spin-drying of wet packed beds can be employed, if the reaction microcavity (104a-h) is placed at a shorter radial distance from the spin axis than the outlet end (114) of the outlet microconduit (113). This is independent of the shape of the outlet microconduit (113).

EXPERIMENTALS

15 Instrumentation

The immunoassay was performed in an automated system. The system (Gyrolab Workstation, prototype 2 instrument equipped with a Laser Induced Fluorescence (LIF) module, Gyros AB, Uppsala, Sweden) was equipped with a CD-spinner, holder for microtiter plates (MTP) and a robotic arm with a holder for 10 capillaries connected to 5 syringe pumps, 2 and 2. Two of the capillaries transferred all the reagents and buffers from a MTP to either of the two common inlet ports (105a-b) in the CD. The other eight capillaries transferred individual samples from a MTP to the separate individual inlet ports (107a-h) in the CD.

25 The Gyrolab Workstation is a fully automated robotic system controlled by application-specific software. An application specific method within the software controls the spinning of the CD at the precisely controlled speeds and thereby controls the movement of liquids through the microstructures as the application proceeds. Special software was included in order to reduce background noise.

30

See also WO 02075312 (Gyros AB), WO 03025548 and US 20030054563 (Gyros AB), WO 03025585 and US 200030055576 (Gyros AB), WO 03056517 and US 200301156763 (Gyros AB) and also www.gyros.com.

Solid phase, immobilization of streptavidin, packing, drying/dehydration and reconstitution

The solid phase bead material packed in the microstructures of the microfluidic device

5 could be of either a porous or solid nature. For example polystyrene (PS) particles (15 μ m, Dynal Biotech, Oslo, Norway) were selected for the solid phase. The beads were modified by passive adsorption of phenyl-dextran (PheDex) to create a hydrophilic surface and were subsequently covalently coupled with streptavidin (Immunopure Streptavidin, Pierce, Perbio Science UK Limited, Cheshire, United

10 Kingdom) using CDAP chemistry (Kohn & Wilchek, Biochem. Biophys. Res. Commun. 107 (1982), 878-884). Other particles as Superdex Peptide and Sepharose HP (Amersham Biosciences, Uppsala, Sweden) have also been covalently coupled with streptavidin using CDAP chemistry (without phenyl-dextran coating).

Streptavidin-biotin is a well-known bioaffinity pair. The polystyrene particles are

15 solid and non-swellable in the reconstitution liquid used. Superdex Peptide and Sepharose HP are porous for many affinity reactants and swellable in the reconstitution liquids used.

After coupling with streptavidin, a suspension of the particles in potassium phosphate

20 buffer (10mM) without bed-preserving agent or with bed-preserving agent (in this case a sugar additive (10-100 mM)) was distributed in the common distribution channel via inlet port (105a-b) and moved through the structure by centrifugal force. The centrifugal force combined with the vents (109a-h,113a-i) divide the suspension in the common inlet arrangement (102) in equal portions, each of which forms a bed

25 of packed particles (column) in each reaction microcavity (104a-h) against the dual depth at the outlet end (111a-h) of each reaction microcavity (104a-h). The approximate volume of the column was 15 nl. The columns/beds were dried/dehydrated by three various methods:

Drying at atmospheric pressure by the aid of wicking: The microfluidic device containing the wet porous beds was spun for one minute at 6000 rpm to remove as much of the fluid as possible before the device was put into a jewel case and sealed in a polymer-coated aluminum bag.

- 5 Vacuum-drying: The microfluidic device containing the wet porous beds was placed on trays and put into a vacuum drying oven (Heraeus vacutherm VT6060M). The temperature was set to 25 °C and the pressure was reduced by vacuum to 0.1 millibars. The device was maintained at this pressure and temperature for half an hours, until the product was dried. The pressure was then allowed to reach 10 atmospheric pressure. The device was then placed into a jewel case and sealed in a polymer-coated aluminum bag.

Freeze-drying (lyophilization): The microfluidic device containing the wet porous beds were placed on a tray and put into a -80 °C freezer. (The device could also be placed in an ordinary -20 °C freezer for an hour.) After a few minutes all columns in the 15 device were freezed and the trays where transferred to a freeze-dryer apparatus (Heto, LyoPro 3000) in which the condenser temperature was set to -57 °C. The pressure was reduced (by vacuum) to 0.1-0.06 millibars. The device was maintained at this pressure and temperature until all of the ice had sublimed (about 12 hours or over night). The pressure was then allowed to reach atmospheric pressure during 2 minutes 20 before the chamber was opened and the lyophilized product was provided in the device. The device was put into a jewel case and sealed in a polymer-coated aluminum bag.

The devices were stored for one month at +4°C after which the dry columns were 25 rewetted/reconstituted once with 15 mM phosphate buffer (PBS), pH 7,4 containing 0.15 M NaCl, 0.02% NaN₃ and 0.01% Tween® 20 via the common distribution channel and spinning at the appropriate rate. Every addition of solution delivers 200 nl liquid to the individual column (104a-h). Finally the function of the reconstituted beds was tested in the immunoassay given below at four different analyte (myoglobin) 30 concentrations and compared with the corresponding beds that had not been dried/dehydrated. The results are presented in figures 4-5 and show that it is more or less imperative to include a bed-preserving agent in order to reconstitute the dry/dehydrated solid phase material to an efficient wet porous bed.

Immunoassay

The catching antibody (= ACs) in our myoglobin assay, the monoclonal antimyoglobin 8E11.1 (LabAS, Tartu, Estonia) was biotinylated using Sulfo-NHS-LC-biotin (Pierce, prod # 21335, Perbio Science UK Limited, Cheshire, United Kingdom). The protein concentration of the monoclonal antimyoglobin 8E11.1 was 1-10 mg/ml and it was incubated in room temperature for 1 h with 3× molar excess of the biotinylation reagent in 15 mM PBS with 0.15 M NaCl before it was gel filtrated through either a NAP-5 column (Amersham Biosciences, Uppsala, Sweden) or a Protein Desalting Spin Column (Pierce, # 89849-P, Perbio Science UK Limited, Cheshire, United Kingdom).

To load the streptavidin immobilized particles with the biotinylated antibody, a solution at a 0.2-2 mg/ml concentration (depending of how much streptavidin it is in the packed column) of antibody was distributed in the common distribution channel via inlet port (105a-b) and moved through the structure by centrifugal force. The flow rate through the columns was controlled by the spin velocity (spin flow 1). After the capturing antibody was attached to the columns they were washed once by addition of PBS (with 0,01% Tween 20) to the common distribution channel (inlet ports 105a or b) followed by a spin step.

To demonstrate the myoglobin assay in Gyrolab Workstation a 6-point standard curve was created (Figure 6). The myoglobin samples (diluted in PBS with 1% BSA) with concentrations in the range of 0-274 nM were distributed to the individual inlet ports (107a-h) by the capillaries. The sample volume 200 nl was defined into the volume-metering unit (108a-h), during the first two steps in the spin flow method. To reach favourable kinetic condition under the capturing step (for myoglobin to bind to 8E11.1) the flow rate of the sample should not exceed 1 nl/sec. The sample flow rate was controlled by spin flow 2. After sample capturing the columns was washed twice by addition PBS (with 0.01% Tween 20) to the common distribution channel (inlet port 105a or b) followed by a spin step. Detecting antibodies (monoclonal antimyoglobin 2F9.1 (LabAs, Tartu, Estonia)) in excess were applied next via the common distribution channel (inlet port 105a or b) and a similar slow flow rate (spin

flow 3) was used. The detecting antibodies were labeled with a fluorophore Alexa 633 (Molecular Probes, Eugene, USA). Excess of labeled antibody was washed away by 4 additions of PBS (with 0,01% Tween 20) to the common distribution channel (inlet port 105a or b) followed by a spin step.

5

The complete assay was analyzed in the Laser Induced Fluorescence (LIF) detector module. See more WO 02075312 (Gyros AB), WO 03025548 and US 20030054563 (Gyros AB), and WO 03056517 and 10/331,399 (Gyros AB).

10 An overview of the run method performed in the system is presented in Table 1.

Table1

METHOD	SPIN PROFILE
Rewetting of bead columns	
Spin 1	2500 rpm 5s, 6000 rpm 10s
Wash of beads	
Spin 2	1200 rpm 2s, 2500 rpm 0,5s, 4000 rpm 10s, 6500 rpm 16s
Transfer of biotinylated antibody	
Spin flow 1	1200 rpm 2s, 2500 rpm 0,5s, from 1200-1500 rpm 45s, 2000 rpm 35s, 3000 rpm 30s, 4000 rpm 10s, 5000 rpm 5s, 6000 rpm 10s
Wash of beads and CD-structure 1	
Spin 3	1200 rpm 2s, 2500 rpm 1s, 4000 rpm 15s, 6000 rpm 18s
Transfer of myoglobin samples	
Spin flow 2	1000 rpm 5s, 2500 rpm 0,5s, from 1200-1500 rpm 90s, 2000 rpm 70s, 3000 rpm 60s, 4000 rpm 20s, 5000 rpm 10s
Myoglobin wash 1	

Spin 4	1200 rpm 2s, 2500 rpm 0,5s, 4000 rpm 10s, 6000 rpm 16s
Myoglobin wash 2	
Spin 5	1200 rpm 2s, 2500 rpm 0,5s, 4000 rpm 10s, 6000 rpm 16s
Transfer of conjugate	
Spin flow 3	1200 rpm 2s, 2500 rpm 0,5s, from 1200- 1500 rpm 90s, 2000 rpm 70s, 3000 rpm 60s, 4000 rpm 20s, 5000 rpm 10s
Conjugate wash 1	
Spin 6	1200 rpm 2s, 2500 rpm 0,5s, 4000 rpm 10s, 6000 rpm 16s
Conjugate wash 2	
Spin 7	1200 rpm 2s, 2500 rpm 0,5s, 4000 rpm 10s, 6000 rpm 16s
Conjugate wash 3	
Spin 8	1200 rpm 2s, 2500 rpm 0,5s, 4000 rpm 10s, 6000 rpm 16s
Conjugate wash 4	
Spin 9	1200 rpm 2s, 2500 rpm 0,5s, 4000 rpm 10s, 6000 rpm 16s
Detection	

Drying and reconstitution

Certain innovative aspects of the invention are defined in more detail in the appending 5 claims. Although the present invention and its advantages have been described in detail, it should be understood that various changes, substitutions and alterations can be made herein without departing from the spirit and scope of the invention as defined by the appended claims. Moreover, the scope of the present application is not intended to be limited to the particular embodiments of the process, machine, 10 manufacture, composition of matter, means, methods and steps described in the specification. As one of ordinary skill in the art will readily appreciate from the

disclosure of the present invention, processes, machines, manufacture, compositions of matter, means, methods, or steps, presently existing or later to be developed that perform substantially the same function or achieve substantially the same result as the corresponding embodiments described herein may be utilized according to the present 5 invention. Accordingly, the appended claims are intended to include within their scope such processes, machines, manufacture, compositions of matter, means, methods, or steps.

C L A I M S

1. A microfluidic device comprising one, two or more microchannel structures (101a-h), each of which comprises a reaction microcavity (104a-h) intended for retaining a solid phase material in the form of a wet porous bed, characterized in that each of said one, two or more microchannel structures (101a-h) comprises the solid phase material in a dry state that comprises a bed-preserving agent comprising one or more compounds having bed-preserving activity.
2. The microfluidic device according of claims 1, characterized in that at least one of said one or more compounds a) exhibit a hydrophilic group that may or may not be non-ionic, and b) are water-soluble.
3. The microfluidic device according to any of claims 1-2, characterized in that at least one of said one or more compounds is a polyol.
4. The microfluidic device according to any of claims 1-3, characterized in that at least one of said one or more compounds exhibits carbohydrate structure, such as polysaccharide structure or oligosaccharide structure.
5. The microfluidic device according to any of claims 1-4, characterized in that at least one of said one or more compounds is a disaccharide, preferably trehalose.
6. The microfluidic device of any of claims 1-5, characterized in that at least one of said compounds is a microcavity adherence agent.
7. The microfluidic device according to any of claims 1-6, characterized in that said dry state comprises a non-volatile buffer, e.g. a phosphate buffer possibly with potassium ion as a counter-ion.
8. The microfluidic device according to 1-7, characterized in that said dry state has been accomplished within the microfluidic device.

9. The microfluidic device according to any of claims 1-8, characterized in that said dry state has been obtained under subatmospheric pressure from the porous bed saturated with an aqueous liquid, for instance above or below the freezing point of the liquid, or by drying the porous bed saturated with water in ambient atmosphere
5 with or without warming.
10. The microfluidic device according to any of claims 1-9, characterized in that
 - a) said solid phase material is in the form of porous or non-porous particles, and
 - b) the porous bed is a packed bed of these particles.
11. The microfluidic device according to any of claims 1-10, characterized in that said solid phase material is swellable or not swellable.
12. The microfluidic device according to any of claims 1-11, characterized in that
15 each of said one, two or more microchannel structures (101a-h) comprises an inlet arrangement (102,103a-h) with a volume-metering unit (106a-h,108a-h) connected to the reaction microcavity (104a-h).
13. The microfluidic device according to any of claims 1-12, characterized in that the
20 device comprises two or more microchannel structures (101a-h) that are divided into one, two or more groups (100) of microchannel structures, each group comprising an inlet arrangement (102) which
 - a) is common to all the microchannel structures of the group (100), and
 - b) comprises
 - 25 (i) a common inlet port (105a-b), and
 - (ii) for each microchannel structure (101a-h) of the group, a volume-metering unit (106a-h) that in the upstream direction is connected to the common inlet (105a-b) port and in the downstream direction to the reaction microcavity (104a-h) of the microchannel structure (101a-h).
- 30 14. The microfluidic device according to any of claims 12-13, characterized in that the inner wall of each of said volume-metering units (106a-h,108a-h) have a sufficient hydrophilicity for being filled by capillarity once an aqueous liquid have


entered the unit, and b) a valve (109a-h,110a-h) at its outlet, for instance a passive valve.

15. The microfluidic device according to any of claims 1-14, characterized in that
5 each microchannel structure (101) is designed for driving a liquid flow through at least a portion of the structure by centrifugal force.
16. The microfluidic device according to any of claims 1-15, characterized in that the solid phase material comprises an immobilized reactant, typically an immobilized
10 affinity reactant AC_S for affinity capturing a solute S .
17. The microfluidic device according to claim 16, characterized in that the immobilized reactant is an immobilized ligand L which is a member of an immobilizing affinity pair comprising L and the affinity counterpart B to L and
15 which is intended for the immobilization of a conjugate $B-AC_S$ to the porous bed where AC_S is an affinity counterpart to a solute S .
18. The microfluidic device according to claim 17 characterized in that the affinity constant (K_{S-AC}) for formation of the complex ($S-AC$) between the solute (S) and
20 the affinity counterpart (AC_S) to the solute, i.e. $(K_{S-AC}) = [S][AC_S]/[S-AC_S]$, is at most 10^{-6} mole/l.
19. The microfluidic device according to claim 18, characterized in that the affinity constant of the immobilizing affinity pair, i.e. $K_{L'-B} = [L'][B']/[L'-B']$, is at most
25 10^3 times larger than the corresponding affinity constant for streptavidin and biotin,
with preference for the affinity pair L' and B' being selected from biotin-binding compounds and streptavidin-binding compounds, respectively, or vice versa.
- 30 20. The microfluidic device according to claim 19, characterized in that B has one or more binding sites for L , and L has two or more binding sites for B , or vice versa.

21. The microfluidic device according to any of claims 16-20, characterized in that at least one of S and AC_S and/or at least one of L, B, AC_S and S comprise a structure selected amongst peptide structure including poly/oligo-peptide and protein structure, carbohydrate structure, nucleotide structure including nucleic acid structure, and lipid structure.

5

Fig. 1



2/7

Figure 2a






Figure 2b.





3/7



Figure 3





4/7

Figure 4a**Figure 4b**


5/7

Figure 5a**Figure 5b**

6/7

Figure 5c**Figure 5d**

7/7

Figure 6

INTERNATIONAL SEARCH REPORT

International application No.
PCT/SE 2004/000440

A. CLASSIFICATION OF SUBJECT MATTER		
<p>IPC7: B81B 1/00 According to International Patent Classification (IPC) or to both national classification and IPC</p>		
B. FIELDS SEARCHED		
Minimum documentation searched (classification system followed by classification symbols)		
<p>IPC7: B01L, B81B, G01N</p>		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
SE,DK,FI,NO classes as above		
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)		
EPO-INTERNAL, WPI DATA		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 6506609 B1 (H. GARRETT WADA ET AL), 14 January 2003 (14.01.2003), column 27, line 33 - line 58, abstract -----	1-21
A	US 2003053934 A1 (PER ANDERSSON ET AL), 20 March 2003 (20.03.2003), abstract -----	1-21
<input type="checkbox"/> Further documents are listed in the continuation of Box C.		<input checked="" type="checkbox"/> See patent family annex.
<p>* Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"B" earlier application or patent but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</p> <p>"&" document member of the same patent family</p>		
Date of the actual completion of the international search		Date of mailing of the international search report
9 June 2004		18-06-2004
Name and mailing address of the ISA/ Swedish Patent Office Box 5055, S-102 42 STOCKHOLM Facsimile No. + 46 8 666 02 86		Authorized officer Mats Raidla /OGU Telephone No. + 46 8 782 25 00

INTERNATIONAL SEARCH REPORT

Information on patent family members

30/04/2004

International application No.

PCT/SE 2004/000440

US	6506609	B1	14/01/2003	US	6592821	B	15/07/2003
				AU	770678	B	26/02/2004
				AU	5015800	A	05/12/2000
				CA	2373347	A	23/11/2000
				EP	1179087	A	13/02/2002
				WO	0070080	A	23/11/2000
<hr/>				US	2003053934	A1	20/03/2003
				CA	2441206	A	26/09/2002
				EP	1384076	A	28/01/2004
				SE	0103117	D	00/00/0000
				WO	02075312	A	26/09/2002
				WO	03024598	A	27/03/2003
				US	2003044322	A	06/03/2003

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.